MedTrace Logo

Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma

NCT02971319 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-01-26

No results posted yet for this study

Summary

This study aims to assess the technical performance of Tc-99m tetrofosmin SPECT as compared to F-18 FDG PET for the differentiation of radiation necrosis from glioma relapse and to obtain estimates of diagnostic accuracy for Tc-99m tetrofosmin SPECT and F-18 FDG PET in an intra-individual comparison.

Conditions

  • Glioma (Diagnosis)

Interventions

DEVICE

Tc-99M-Tetrofosmin SPECT

DEVICE

F-18 FDG PET

Sponsors & Collaborators

  • ConsulTech GmbH

    collaborator UNKNOWN

  • pharmtrace

    collaborator UNKNOWN

  • Pharmathen S.A.

    collaborator INDUSTRY

  • Proactina S.A.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-11-17
Completion
2017-12-17

Countries

  • France
  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02971319 on ClinicalTrials.gov